Alx Oncology Holdings annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
Alx Oncology Holdings R&D Spending Growth & History (ALXO)
Alx Oncology Holdings's r&d spending was $77.0M for fiscal 2025.
View full Alx Oncology Holdings company overviewAlx Oncology Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $77.0M | −$39.4M | −33.84% |
| 2024 | 2024-12-31 | $116.4M | −$25.4M | −17.93% |
| 2023 | 2023-12-31 | $141.8M | $43.4M | +44.10% |
| 2022 | 2022-12-31 | $98.4M | $38.2M | +63.54% |
| 2021 | 2021-12-31 | $60.2M | $31.2M | +107.76% |
| 2020 | 2020-12-31 | $29.0M | $12.7M | +77.61% |
| 2019 | 2019-12-31 | $16.3M | $5.0M | +44.69% |
| 2018 | 2018-12-31 | $11.3M | — | — |
Alx Oncology Holdings quarterly r&d spending
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $13.1M | −$4.9M | −27.10% |
| Q1 2026 | 2026-03-31 | $13.6M | −$10.3M | −43.04% |
| Q4 2025 | 2025-12-31 | $17.6M | −$5.9M | −25.02% |
| Q3 2025 | 2025-09-30 | $17.4M | −$9.0M | −34.11% |
| Q2 2025 | 2025-06-30 | $18.0M | −$16.6M | −47.99% |
| Q1 2025 | 2025-03-31 | $23.9M | −$7.8M | −24.68% |
| Q4 2024 | 2024-12-31 | $23.5M | −$18.3M | −43.68% |
| Q3 2024 | 2024-09-30 | $26.5M | −$19.3M | −42.16% |
| Q2 2024 | 2024-06-30 | $34.7M | $5.2M | +17.54% |
| Q1 2024 | 2024-03-31 | $31.7M | $7.0M | +28.08% |
| Q4 2023 | 2023-12-31 | $41.8M | $16.6M | +65.83% |
| Q3 2023 | 2023-09-30 | $45.8M | $16.4M | +55.76% |
| Q2 2023 | 2023-06-30 | $29.5M | $2.7M | +10.22% |
| Q1 2023 | 2023-03-31 | $24.8M | $7.7M | +45.04% |
| Q4 2022 | 2022-12-31 | $25.2M | $4.3M | +20.59% |
| Q3 2022 | 2022-09-30 | $29.4M | $11.2M | +61.32% |
| Q2 2022 | 2022-06-30 | $26.7M | $15.5M | +138.54% |
| Q1 2022 | 2022-03-31 | $17.1M | $7.2M | +73.35% |
| Q4 2021 | 2021-12-31 | $20.9M | $8.8M | +72.08% |
| Q3 2021 | 2021-09-30 | $18.2M | $12.9M | +241.85% |
| Q2 2021 | 2021-06-30 | $11.2M | $3.5M | +46.33% |
| Q1 2021 | 2021-03-31 | $9.8M | $6.0M | +157.29% |
| Q4 2020 | 2020-12-31 | $12.1M | — | — |
| Q3 2020 | 2020-09-30 | $5.3M | $3.1M | +141.09% |
| Q2 2020 | 2020-06-30 | $7.7M | $4.0M | +111.22% |
| Q1 2020 | 2020-03-31 | $3.8M | — | — |
| Q3 2019 | 2019-09-30 | $2.2M | — | — |
| Q2 2019 | 2019-06-30 | $3.6M | — | — |
Alx Oncology Holdings r&d spending trends
Over the last five fiscal years, Alx Oncology Holdings's r&d spending increased from $29.0M to $77.0M, a change of $48.0M. The latest reported quarter, Q2 2026, shows $13.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alx Oncology Holdings source filings ↗